Vertex Pharmaceuticals Incorporated

180 articles about Vertex Pharmaceuticals Incorporated

• European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years

  1/11/2022

  Vertex Pharmaceuticals Incorporated announced that the European Commission has granted approval for the label extension of KAFTRIO® in a combination regimen with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

• Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

  12/1/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

• Vertex to Announce Third-Quarter 2021 Financial Results on November 2

  10/22/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close.

• Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)

  10/19/2021

  Vertex Pharmaceuticals Incorporated today announced that five scientific abstracts about the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 2021 North American Cystic Fibrosis Conference (NACFC) taking place virtually November 2-5, 2021.

• Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th

  9/13/2021

  Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th

• Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

  8/26/2021

  Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

• Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies

  8/24/2021

  Vertex Pharmaceuticals Incorporated and Arbor Biotechnologies announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases.

• Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer

  8/4/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the company’s Executive Vice President, Chief Operating Officer (COO), effective immediately.

• Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

  7/19/2021

  Vertex Pharmaceuticals Incorporated today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the selective NaV1.8 inhibitor VX-548.

• Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

  6/9/2021

  Vertex Announces U.S. FDA Approval for TRIKAFTA ® in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations.

• Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million

  5/17/2021

  Concert Pharmaceuticals, Inc. announced that Vertex Pharmaceuticals Incorporated has purchased the potential future milestones under the companies’ 2017 asset purchase agreement relating to VX-561 for $32 million.

• Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

  4/20/2021

  Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001

• CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

  12/5/2020

  The New England Journal of Medicine publishes CTX001 manuscript containing the first report of investigational use of CRISPR/Cas9-based gene editing to treat inherited diseases in humans

• Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years

  11/27/2020

  The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations

• Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation

  11/13/2020

  Vertex Pharmaceuticals Incorporated announced that it has been notified of an unsolicited “mini-tender” offer dated November 9, 2020, made by TRC Capital Investment Corporation, an Ontario, Canada, corporation to purchase up to 1,000,000 shares of Vertex common stock.

• Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age

  11/5/2020

  Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe

• Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators

  9/24/2020

  Oral presentation of interim results from TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) open-label safety extension study to be presented at the ECFS Digital Conference

•  Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation

  9/14/2020

  Vertex Pharmaceuticals Incorporated announced the European Medicines Agency has validated a Type II Variation Marketing Authorization Application for the expanded indication of KAFTRIO®* in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

• CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes

  6/26/2020

  If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease

• Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice

  6/25/2020

  Vertex Foundation Announces $1.5 Million Gift to Boston University’s New Center for Antiracist Research